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Validation of plasma fibrinogen as a marker of
carotid atherosclerosis in subjects free of clinical
cardiovascular disease
Increasing evidence indicates that thehemostatic system plays an importantrole in the pathogenesis of atheroscle-
rotic vascular disease.1 Numerous epidemi-
ological studies have documented the asso-
ciation of  elevated plasma fibrinogen lev-
els  with increased incidence of cardiovas-
cular disease.2-8 There is also evidence that
fibrinogen may have a role in acute and
inflammatory processes, being involved in
the development of atherosclerosis and its
complications.9,10 An important issue is
whether fibrinogen is related to cardiovas-
cular abnormalities in subjects in whom
there is no evidence of overt atherosclerot-
ic disease.11 In a recent study,12 we showed
an independent association of fibrinogen
concentration with carotid intima-media
thickness (IMT), a non-invasive marker of
subclinical atherosclerosis, known to be
associated with prevalent heart disease and
with cardiovascular risk factors.13,14 Howev-
er, controversy still exists as regards the
relations of fibrinogen to markers of sub-
clinical atherosclerosis.15
Therefore, we tried to validate the meas-
urement of plasma fibrinogen both in rela-
tion to carotid IMT and atheroma plaques
in a wider population of adults free of clin-
ically overt cardiovascular disease.
Design and Methods
Subjects
A total of 519 consecutive apparently
healthy subjects (420 males, 80%), median
age 55.5±10.7 years (range 28 to 71 years)
referred to the outpatient clinic for vascu-
lar risk assessment by the Internal Medicine
Department at the University Hospital of
Navarra were studied. All subjects were
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Background and Objectives. Fibrinogen has been found to be an independent risk fac-
tor for cardiovascular disease. The aim of this study was to validate the measurement of
plasma fibrinogen as a marker of subclinical atherosclerosis in a series of asymptomatic
subjects (n=519, median age 55.5 years, 80% men). 
Design and Methods. All individuals had a complete clinical examination, lipid profile
(cholesterol and its high and low density lipoprotein fractions and triglycerides), global
vascular risk assessment (PROCAM), and B-mode ultrasonography of the carotid arteries
to determine the intima-media thickness (IMT) and the presence of atheroma plaques. C-
reactive protein (CRP), and von Willebrand factor (vWF) were also measured in all sub-
jects as markers of inflammation/endothelial damage. 
Results. In the univariate model, a positive relationship was found between plasma fib-
rinogen concentration and carotid IMT (p<0.001). Fibrinogen concentration also corre-
lated positively with age (p<0.001), systolic blood pressure (p<0.001), smoking (p<0.05),
diabetes (p<0.05), PROCAM (p<0.001), CRP and vWF (p<0.001). In the multivariate analy-
sis, the association of fibrinogen with carotid IMT remained significant (p=0.008) after
adjustment for all parameters analyzed.
Interpretation and Conclusions. In a population sample of adults without clinically overt
atherosclerotic disease, elevated fibrinogen levels was related to carotid IMT independ-
ently of a wide range of important confounding variables. Plasma fibrinogen may repre-
sent a systemic marker of carotid atherosclerosis.
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interviewed to exclude individuals with a history of
coronary artery disease (CAD) or previous vascular sur-
gery. Additional exclusion criteria were the presence of
severely impaired renal function, arteritis, collagen dis-
ease, and a history of alcohol abuse. 
Assessment of cardiovascular risk factors
In addition to questions about symptoms of
ischemic heart disease, peripheral vascular disease
and stroke, information on the cardiovascular risk
factors diabetes mellitus, arterial hypertension and
smoking were obtained. The subject was defined as
having hypertension if he or she was being treated
with antihypertensive drugs at the time of examina-
tion or had a systolic blood pressure greater than 140
mmHg and/or diastolic pressure greater than 90
mmHg. Subjects with a positive history of diabetes
mellitus or with fasting glucose levels higher than
7.0 mmol/L were considered diabetic. As far as con-
cerns smoking, individuals were categorized as ever
smokers or non-smokers. Obesity was estimated by
the body mass index (BMI, kg/m2). Dyslipidemia was
diagnosed in the presence of at least one of the fol-
lowing measurements: total cholesterol >200 mg/dL,
low density lipoprotein (LDL)-cholesterol >135
mg/dL, and high density lipoprotein (HDL)-choles-
terol <35 mg/dL.
Measurement of global cardiovascular risk 
The PROCAM score for global CVD risk was
obtained in every person as previously reported.16
Written informed consent was obtained from the
subjects. Procedures followed were in accordance
with the ethical standards approved by the institu-
tional review board of the University Clinic of Navar-
ra and with the Helsinki Declaration.
Laboratory data
Determination of  plasma fibrinogen 
Blood was collected by venipuncture between 9-11
a.m. after 12 hours of fasting. Venous blood was mixed
(9:1) with sodium citrate solution 0.11 mol/L and
immediately centrifuged at 2000g for 20 min at 4°C.
The platelet-poor plasma was then frozen at -80°C
until assayed. Plasma fibrinogen activity was meas-
ured on citrated plasma samples by the Clauss
method17 on a Electra coagulometer 1600 (MLA, USA)
using Hemoliance Q.F.A. thrombin (IL, USA). The intra-
and inter-assay coefficients of variation for the fib-
rinogen assay were 4% and 5.5%, respectively.
Lipid measurements
Serum cholesterol, HDL and LDL-cholesterol, glu-
cose and triglycerides were measured on fasting
blood samples by standard enzymatic techniques.
Markers of inflammation and/or endothelial
damage
von Willebrand factor antigen was quantified by
an enzyme-linked immunosorbent assay (ELISA,
Diagnostica Stago) using a STA compact analyzer
(Diagnostica Stago, France). High-sensitivity C reac-
tive protein (Immulyte hs-CRP) was measured by
ELISA.18 Inter- and intra-assay coefficients of varia-
tion for all ELISAs were lower than 8%.
Measurement of carotid IMT and presence of
atheroma plaques
All subjects underwent ultrasonography of the
common carotid arteries. Ultrasonography was per-
formed with a 5-to 12-MHz linear-array transducer
(ATL 500 HDI). The IMT was measured 1 cm proximal
to the carotid bulb of each common carotid artery at
plaque-free sites. For each individual, the IMT was
determined as the average of near-wall and far-wall
measurements of each common carotid artery, which
has been shown to be a reproducible strategy.1,12
Atheroma plaques were defined as echogenic struc-
tures encroaching the vessel lumen with a distinct
area 50% greater than the intimal plus media thick-
ness of neighboring sites.
Statistical analysis 
The distribution of continuous variables in groups
was expressed as mean±SD. Differences in the base-
line characteristics were evaluated by the Student's
t test and χ2 tests when appropriate. Pearson`s cor-
relation tests were used to analyze the relationship
between two continuous variables. Linear regression
analysis and multivariate analysis were carried out to
evaluate factors related to carotid IMT as well as the
possibility of interactions. Statistical analysis was
performed with SPSS for Windows software package
version 11.0. For all these analyses the level of sta-
tistical significance was established as a p value
< 0.05.
Results
Clinical and laboratory data
After exclusion criteria, 519 apparently healthy sub-
jects (420 men, median age 55 years) were included.
Baseline clinical characteristics, cardiovascular risk
factors, PROCAM score and circulating levels of mark-
ers of inflammation and endothelial damage  in the
whole population are shown in Table 1. The prevalence
of cardiovascular risk factors was as follows: dyslipi-
demia (90.2%), arterial hypertension (52.2%), smok-
ing (33.8%), obesity (29.2%), and diabetes (11.4%).
There were more smokers among males and their BMI
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was significantly higher (p<0.001). In addition, com-
pared with female patients, the male subjects had sig-
nificantly higher plasma levels of triglycerides and
lower HDL-cholesterol (p<0.001). Finally, carotid IMT
was greater in males (0.75 mm vs 0.68 mm in females,
p<0.001), and carotid plaques were more common  in
the males (p=0.041).
Fibrinogen levels in relation to ultrasound
analysis, clinical and laboratory data
The median plasma fibrinogen level in the whole
studied population was 306.6 mg/dL (range 83-508
mg/dL). A significant correlation was observed in the
univariate analysis between plasma fibrinogen con-
centration and carotid IMT, as estimated by B-mode
ultrasound (r=0.18, p<0.001). As shown in Table 2, fib-
rinogen was also positively associated with age
(r=0.18, p<0.001), diabetes (r=0.10, p<0.02), smoking
(r=0.12, p<0.05) and systolic blood pressure (r=0.14,
p<0.001). The levels of fibrinogen also correlated sig-
nificantly with CRP (r=0.27, p<0.001) and vWF
(r=0.25, p<0.001). Finally, a significant correlation was
found between baseline fibrinogen levels and the PRO-
CAM score (r=0.27, p<0.001). 
The carotid IMT (Table 3) also correlated positively
with age (r=0.32, p<0.001), hypertension (r=0.31,
p<0.001), gender (r=0.16, p<0.001), glucose (r=0.17,
p<0.001), total cholesterol (r=0.11, p<0.01) and the
PROCAM score (r=0.32 and p<0.001 ). 
Finally, fibrinogen levels were significantly higher in
patients with plaque (n=107) than in those with no
plaque (321.8±89.9 vs 300.2±71.9 mg/dL, p=0.016).
Multivariate analysis
Because of the important associations of fibrinogen
and carotid IMT with older age, male gender, hyper-
tension and diabetes, further multivariate analysis was
performed to assess the relationship between fibrino-
gen and carotid IMT after adjusting for these poten-
tial confounders (Table 4). Results showed that the
relation between both parameters remained statisti-
Table 1. Baseline clinical characteristics of the studied population.
Total population Male Female p
(n=519) (n=420) (n=99) value
Age (years) 55.5±10.7 55.6±10.7 56.5±10.7 n.s.
Smokers (no/yes) 343/176 278/142 82/17 0.001
BMI (Kg/m2) 28.0±4.1 28.4±3.7 26.2±4.4 <0.001
SBP (mm Hg) 132.1±19.9 131.8±19.9 133.4±20.4 n.s.
Arterial hypertension (no/yes) 248/271 198/222 47/52 n.s.
Diabetes mellitus (no/yes) 460/59 365/55 89/10 n.s.
Total cholesterol (mg/dL) 229.1±43.6 227.6±42.6 235.6±47.3 n.s.
HDL-cholesterol (mg/dL) 49.5±13.9 47.3±12.8 59.6±14.5 <0.001
LDL-cholesterol (mg/dL) 155.7±38.2 155.8±37.9 155.2±39.6 n.s.
Triglycerides (mg/dL)† 124.5±87.0 128.9±90.4 104.4±66.8 0.006
CRP (mg/L)† 4.7±9.5 4.7±9.4 4.9±10.4 n.s.
Fibrinogen (mg/dL) 306.6±77.4 304.7±77.9 315.2±74.6 n.s.
vWF (%) 120.4±58.5 120.3±59.8 121.1±52.8 n.s.
Risk score (PROCAM)† 1.3±1.5 1.3±1.5 − −
Carotid IMT (mm) 0.74±0.16 0.75±0.16 0.68±0.14 <0.001
Carotid plaque (N/Y) 412/107 326/94 86/13 0.041
BMI: body mass index; SBP: systolic blood pressure; CRP: C-reactive protein; vWF: von Willebrand factor; (Mean±SD); †logarithmically transformed variables.
Table 2. Pearson’s correlation coefficients between fib-
rinogen and cardiovascular risk factors, inflammatory and
endothelial markers and carotid IMT.
Parameter r p value
Risk factors
Age (years) 0.18 <0.001
BMI (kg/m2) 0.07 n.s.
SBP (mm Hg) 0.14 0.001
Cholesterol (mg/dL) 0.05 n.s.
LDL-cholesterol (mg/dL) 0.02 n.s.
HDL- cholesterol (mg/dL) -0.06 n.s.
Triglycerides (mg/dL) 0.01 n.s.
Diabetes mellitus (yes/no) 0.10 0.02
Smoking (yes/no) 0.12 0.036
Inflammatory/endothelial markers
CRP (mg/L) 0.27 <0.001
vWF (%) 0.25 <0.001
PROCAM
Risk score 0.27 <0.001
Ultrasound studies
Carotid IMT (mm) 0.18 <0.001
Abbreviations as in Table 1.
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cally significant (p=0.008). Since there is evidence that
fibrinogen plasma levels may reflect a systemic
inflammatory state, further adjustment was made for
markers of inflammation and endothelial damage.
Results showed that the association between fibrino-
gen and carotid IMT was independently related to
these parameters (adjusted R2= 0.21, p<0.001).
Discussion
In a population sample of adults free of clinically
overt atherosclerotic disease, we found that an ele-
vated plasma fibrinogen concentration was related to
carotid IMT, a surrogate marker of  atherosclerosis,
independently of a wide range of important con-
founding variables, confirming previous data in a
smaller population.12 A significant relationship was
also detected when fibrinogen was compared with the
presence of carotid plaques. Our data underscore the
relevance of measuring the circulating levels of plas-
ma fibrinogen as a marker of subclinical atheroscle-
rosis in asymptomatic subjects.  Elevated levels of fib-
rinogen are strongly associated with human vascular
disease.19,20 The Northwick Park Heart Study found that
elevated fibrinogen at recruitment was independent-
ly associated with subsequent cardiovascular risk, with
an increase of approximately 70 mg/dL being associ-
ated with a 39% increase in cardiac death and a 60%
increase in non-fatal myocardial infarction.2 It is
unknown, however, whether increased fibrinogen plays
a causal role in vascular disease progression. Elevated
plasma fibrinogen may promote vascular disease by
increasing blood viscosity, promoting fibrin formation,
enhancing platelet-platelet interactions, or by other
mechanisms.19 On the other hand, elevated plasma fib-
rinogen could simply be a marker of vascular disease,
but does not contribute to disease progression.21 Fib-
rinogen production in the liver is regulated by
cytokines and is greatly enhanced in response to dif-
ferent inflammatory processes.9,10,22 It is, therefore, pos-
sible that moderately elevated fibrinogen levels sim-
ply reflect the chronic inflammation that characterizes
atherosclerosis.23
In the population analyzed, fibrinogen levels were
significantly associated with the PROCAM score, and
also with some traditional cardiovascular risk factors,
such as hypertension and diabetes, suggesting a close
relationship between fibrinogen and a variety of envi-
ronmental factors, as previously reported.4,24 The levels
of fibrinogen positively correlated with  markers of
inflammation and endothelial damage (CRP and vWF,
respectively), also confirming previous findings in clin-
ical and epidemiological studies.25 The association
between the plasma fibrinogen concentration and the
levels of these inflammatory markers emphasizes the
importance of inflammatory processes in the devel-
opment of atherosclerosis, as already described for
patients with coronary syndromes.25,26
We, therefore, performed a multivariate analysis to
determine whether the association between fibrino-
gen levels and carotid IMT still remained significant
when the environmental factors showing significant
associations in the univariate analysis were taken into
consideration. Our results confirmed that  fibrinogen
concentration represents an independent marker of
subclinical atherosclerosis in asymptomatic subjects.
The association between fibrinogen and carotid IMT
remained highy significant after adjusting for cardio-
vascular risk factors (age, BMI, diabetes, and arterial
blood pressure) as well as for markers of inflammation
(CRP) and endothelial damage (vWF). In contrast, CRP
showed no association with carotid IMT, confirming
that CRP levels do not correlate well with imaging
measures of underlying atherosclerosis.27 We also
Table 3. Correlation of the carotid IMT with all other vari-
ables investigated.
R p value
Age (years) 0.32 <0.001
Gender (M/F) 0.16 <0.001
BMI (Kg/m2) 0.06 n.s.
SBP (mmHg) 0.31 <0.001
DBP (mmHg) 0.11 0.01
Total cholesterol (mg/dL) 0.11 0.02
HDL-cholesterol (mg/dL) - 0.01 n.s.
LDL-cholesterol (mg/dL) 0.11 0.01
Triglycerides (mg/dL) 0.05 n.s.
Glucose (mg/dL) 0.17 <0.001
Smoking (yes/no) 0.06 n.s.
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood
pressure.
Table 4. Correlation of the carotid IMT with fibrinogen in
multiple linear regression analysis  with carotid IMT (mm)
as dependent variable. 
β(×10-3) SE (β) p* Partial R2 (%)
Fibrinogen (mg/dL) 0.23 0.08 0.008 1.4
Sex (F/M) 73,2 10.0 <0.001 3.2
Age (years) 4.1 0.66 <0,001 6.9
SBP (mmHg) 1.7 0.34 <0.001 4.5
Glucose (mg/dL) 0.58 0.21 0.012 1.2
LDL-cholesterol 0.45 0.10 0.008 1.1
Smoking (no/yes) 38,9 14.3 0.006 1.4
*Adjusted for age, sex, BMI, SBP, LDL-cholesterol, glucose, smoking, CRP
and vWF. The model  R2 for the total population was 21.3%
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showed that fibrinogen levels were significantly high-
er in patients with carotid plaques.
Higher fibrinogen levels could be one of the many
mechanisms by which fibrinogen plays a role in the
pathogenesis of atherosclerosis. It is interesting to noe
that hyperfibrinogenemia was associated with the his-
tological composition of atherosclerotic carotid
plaques in patients with transient ischemic attacks
and coronary disease.28,29 Studies examining transgenic
mice models of hyperfibrinogenemia also suggested
that fibrinogen has a role in vascular disease progres-
sion.30,31 In a transgenic model of modest hyperfibrino-
genemia, Kerlin et al. recently showed that fibrinogen
alters vascular remodeling induced by ligation of the
carotid artery, producing augmented intimal hyper-
plasia compared to that occurring in wild-type con-
trols.32 Conversely, fibrinogen deficiency reduced vas-
cular accumulation and development of atherosclero-
sis in apolipoprotein(a) transgenic mice.33
Our study has some limitations. Although other
chronic conditions that may influence fibrinogen syn-
thesis were excluded, the possibility that the observed
elevated fibrinogen was a result, rather than a cause
of subclinical atherosclerosis, cannot be ruled out. 
Since the majority of individuals enrolled were dys-
lipidemic, the results are mainly valid for this specific
vascular risk subgroup. In the multivariate analysis we
tried to adjust for some but not all the possible con-
founders and it is known that other genetic, metabol-
ic and environmental factors not included in the pres-
ent analysis could influence the fibrinogen levels.34,35
However, in a previous pilot study we could not con-
firm a relationship between the -455 G/A β-fibrino-
gen polymorphism and carotid IMT.12 Finally, the sam-
ple size means that the results cannot automatically
be extrapolated to other populations at risk for CVD.
In conclusion, our results strongly suggest that plas-
ma fibrinogen concentration can be an independent
marker of subclinical atherosclerosis in asymptomatic
subjects. Further studies are required to establish
whether modest hyperfibrinogenemia contributes to
the development of atherothrombotic diseases, par-
ticularly coronary heart disease.
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